LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Strona główna・Stock List・Guardant Health Inc

Guardant Health Inc

Closed

SectorHealthcare

92.26 3.13

Buy Sell

Overview

Share price change

24h

Current

Min

Max

92.72

Key metrics
By Trading Economics
Income	-36M -128M
Sales	16M 281M
EPS	-0.5
Profit margin	-45.684
Employees	2,490
EBITDA	-37M -119M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+41.31% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.5B 12B
Previous open	89.13
Previous close	92.26

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

38.86 / 47.41 Support & Resistance

Guardant Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 maj 2026, 23:41 UTC

Earnings

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 maj 2026, 21:40 UTC

Earnings

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 maj 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 maj 2026, 23:13 UTC

Earnings

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 maj 2026, 23:13 UTC

Earnings

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 maj 2026, 23:12 UTC

Earnings

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 maj 2026, 23:11 UTC

Earnings

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 maj 2026, 23:11 UTC

Earnings

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 maj 2026, 23:07 UTC

Earnings

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 maj 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 maj 2026, 23:06 UTC

Earnings

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 maj 2026, 23:05 UTC

Earnings

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 maj 2026, 23:04 UTC

Earnings

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 maj 2026, 22:50 UTC

Earnings

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 maj 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 maj 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 maj 2026, 22:11 UTC

Earnings

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 maj 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 maj 2026, 21:58 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 maj 2026, 21:47 UTC

Market Talk

Earnings

Costco Posts 13% Sales Growth in April -- Market Talk

6 maj 2026, 21:46 UTC

Earnings

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 maj 2026, 21:40 UTC

Earnings

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 maj 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 maj 2026, 21:32 UTC

Hot Stocks

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 maj 2026, 21:29 UTC

Earnings

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

41.31% upside

12 Months Forecast

Average 128.83 USD 41.31%

High 175 USD

Low 85 USD

Based on 18 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Guardant Health Inc - Dist in the past 3 months.

Technical Score

By Trading Central

38.86 / 47.41Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.